Literature DB >> 21247525

Placental growth factor and B-type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers [ARROW]) study.

Ruchira Glaser1, W Frank Peacock, Alan H B Wu, Reinhold Muller, Martin Möckel, Fred S Apple.   

Abstract

Most patients presenting to the emergency department with possible cardiac symptoms have low cardiac troponin (cTn) concentrations. A combination of biomarkers that improves risk stratification in patients at very low risk for major adverse cardiovascular events (MACEs) would be beneficial. In this multicenter prospective cohort study, specimens from 598 subjects presenting to 5 emergency departments with suspected acute coronary syndromes were collected on arrival and serially for traditional and novel biomarkers. Subjects were evaluated for MACEs, defined as death, myocardial infarction, or revascularization at 30 and 365 days. Classification and regression tree analysis assessed biomarker and clinical factors associated with MACEs. The 1-year rate of MACE was 10.5% (47 of 449). Rates of death, myocardial infarction, and revascularization were 4.2%, 1.6%, and 4.7%, respectively. The combination of B-type natriuretic peptide (BNP), placental growth factor (PlGF), and estimated glomerular filtration rate (eGFR) was the most accurate predictor of MACEs compared to any other biomarker or clinical factors including cTnI. If BNP was ≤ 65 ng/L and PlGF was ≤ 19.5 ng/L, the negative predictive value for 1-year MACEs was 99.1%. Conversely, BNP >150 ng/L and eGFR ≤ 68 ml/min/1.73 m(2) predicted a very high (36.5%) MACE rate. Prognostic values of BNP and PlGF were incremental (none increased, 2 of 212, 0.9%; only PlGF increased, 30 of 170, 17.6%; only BNP increased, 33 of 153, 21.6%; BNP and PlGF increased, 18 of 86, 20.9%). Considering only initial emergency department samples, 97% and 96% of patients with normal PlGF, BNP, and cTnI levels were event-free at 30 and 365 days, respectively. In conclusion, the combination of BNP, PlGF, and eGFR is the most accurate in risk-stratifying patients with suspected acute coronary syndrome.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21247525     DOI: 10.1016/j.amjcard.2010.11.003

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

Authors:  Claire Sweeney; Fiona Ryan; Mark Ledwidge; Cristin Ryan; Ken McDonald; Chris Watson; Rebabonye B Pharithi; Joe Gallagher
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

2.  Angiogenic Factors and Risks of Technique Failure and Cardiovascular Events in Patients Receiving Peritoneal Dialysis.

Authors:  Masaru Matsui; Ken-Ichi Samejima; Yukiji Takeda; Katsuhiko Morimoto; Miho Tagawa; Kenji Onoue; Satoshi Okayama; Hiroyuki Kawata; Rika Kawakami; Yasuhiro Akai; Hiroyuki Okura; Yoshihiko Saito
Journal:  Cardiorenal Med       Date:  2016-03-31       Impact factor: 2.041

Review 3.  Role of placenta growth factor in cancer and inflammation.

Authors:  Ki Jo Kim; Chul Soo Cho; Wan Uk Kim
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

4.  Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.

Authors:  Masaru Matsui; Shiro Uemura; Yukiji Takeda; Ken-Ichi Samejima; Takaki Matsumoto; Ayako Hasegawa; Hideo Tsushima; Ei Hoshino; Tomoya Ueda; Katsuhiko Morimoto; Keisuke Okamoto; Sadanori Okada; Kenji Onoue; Satoshi Okayama; Hiroyuki Kawata; Rika Kawakami; Naoki Maruyama; Yasuhiro Akai; Masayuki Iwano; Hideo Shiiki; Yoshihiko Saito
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

5.  [Effects of antihyperglycemics on endothelial progenitor cells].

Authors:  Xue Han; Guojun Jiang; Qiaojuan Shi
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

Review 6.  Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers.

Authors:  Michela Chianca; Giorgia Panichella; Iacopo Fabiani; Alberto Giannoni; Serena L'Abbate; Alberto Aimo; Annamaria Del Franco; Giuseppe Vergaro; Chrysanthos Grigoratos; Vincenzo Castiglione; Carlo Maria Cipolla; Antonella Fedele; Claudio Passino; Michele Emdin; Daniela Maria Cardinale
Journal:  Front Cardiovasc Med       Date:  2022-07-06

7.  Plasma Placental Growth Factor Concentrations Are Elevated Well in Advance of Type 2 Diabetes Mellitus Onset: Prospective Data From the WHS.

Authors:  Edward K Duran; Nancy R Cook; Maria Bobadilla; Eunjung Kim; JoAnn E Manson; Julie E Buring; Paul M Ridker; Aruna D Pradhan
Journal:  J Am Heart Assoc       Date:  2019-07-19       Impact factor: 5.501

8.  Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management.

Authors:  Antoine Kossaify; Annie Garcia; Sami Succar; Antoine Ibrahim; Nicolas Moussallem; Mikhael Kossaify; Gilles Grollier
Journal:  Biomark Insights       Date:  2013-09-03

9.  B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study.

Authors:  Rakesh K Mishra; Alexis L Beatty; Rajesh Jaganath; Mathilda Regan; Alan H B Wu; Mary A Whooley
Journal:  J Am Heart Assoc       Date:  2014-07-22       Impact factor: 5.501

Review 10.  Multiple therapeutic effect of endothelial progenitor cell regulated by drugs in diabetes and diabetes related disorder.

Authors:  Rashmi K Ambasta; Harleen Kohli; Pravir Kumar
Journal:  J Transl Med       Date:  2017-08-31       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.